Literature DB >> 11857400

Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain.

Sílvia de Sanjosé1, Vickie Marshall, Judit Solà, Virgilio Palacio, Rosa Almirall, James J Goedert, F Xavier Bosch, Denise Whitby.   

Abstract

Transmission routes of Kaposi's sarcoma-associated herpesvirus (KSHV) in the general population are poorly understood. Whereas sexual transmission appears to be common in homosexual men, the evidence for heterosexual transmission is less convincing. In our study, prevalence of KSHV infection was examined among women in the Spanish general population and among sex workers. Subjects consisted of 100 prostitutes and 100 women randomly sampled from the general population and age-matched to the prostitutes. Women had a personal interview and gynecologic examinations in which a blood sample, cervical cells and oral cells were obtained. Peripheral blood mononuclear cells (PBMC), oral and cervical samples were tested for KSHV DNA by quantitative real-time PCR. Sera were tested for antibodies against human immunodeficiency virus (HIV) by ELISA and against KSHV by latent IFA and K8.1 ELISA. Women who were positive in either serologic assay or PCR were considered infected by KSHV. Human papillomavirus (HPV) DNA in cervical scrapes were evaluated using the Hybrid Capture System. The study population had an average age of 30 years and were HIV-negative. Women from the general population were largely of Spanish nationality, and 61% reported lifetime monogamy. The majority of the prostitutes (76%) were immigrants, primarily from South America. Sex workers were twice as likely to be infected with KSHV than women in the general population (16% vs. 8%, prevalence odds ratio [OR] = 2.2). KSHV was more prevalent among HPV DNA-positive women (OR = 2.5) and among women with an early age at first sexual intercourse (OR = 2.7, p < 0.05). KSHV DNA was detected by PCR in 3% of the oral cavity samples, in 2% of the cervical samples of the prostitutes and in 1% of the cervical samples of women in the general population. All PBMC samples were negative. These results suggest that in low-risk countries for KSHV, oral shedding and heterosexual contacts are potential pathways for KSHV transmission. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857400     DOI: 10.1002/ijc.10190

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

1.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  KSHV co-infection regulates HPV16+ cervical cancer cells pathogenesis in vitro and in vivo.

Authors:  Lu Dai; Jing Qiao; Luis Del Valle; Zhiqiang Qin
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 3.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

4.  Kaposi's sarcoma-associated herpesvirus microRNA single-nucleotide polymorphisms identified in clinical samples can affect microRNA processing, level of expression, and silencing activity.

Authors:  Soo-Jin Han; Vickie Marshall; Eugene Barsov; Octavio Quiñones; Alex Ray; Nazzarena Labo; Matthew Trivett; David Ott; Rolf Renne; Denise Whitby
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

5.  Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda.

Authors:  Angela Nalwoga; Marjorie Nakibuule; Vickie Marshall; Wendell Miley; Nazzarena Labo; Stephen Cose; Denise Whitby; Robert Newton
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome.

Authors:  Alex Ray; Vickie Marshall; Thomas Uldrick; Robert Leighty; Nazzarena Labo; Kathy Wyvill; Karen Aleman; Mark N Polizzotto; Richard F Little; Robert Yarchoan; Denise Whitby
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

7.  Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands.

Authors:  Jennifer T Miller; Haiyan Zhao; Takashi Masaoka; Brittany Varnado; Elena M Cornejo Castro; Vickie A Marshall; Kaivon Kouhestani; Anna Y Lynn; Keith E Aron; Anqi Xia; John A Beutler; Danielle R Hirsch; Liang Tang; Denise Whitby; Ryan P Murelli; Stuart F J Le Grice
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Deirdre O'Mahony; Kathleen M Wyvill; Victoria Wang; Vickie Marshall; Stefania Pittaluga; Seth M Steinberg; Giovanna Tosato; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

9.  Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions.

Authors:  Denise Whitby; Vickie A Marshall; Rachel K Bagni; Wendell J Miley; Thomas G McCloud; Rebecca Hines-Boykin; James J Goedert; Betty A Conde; Kunio Nagashima; Judy Mikovits; Dirk P Dittmer; David J Newman
Journal:  Int J Cancer       Date:  2007-01-15       Impact factor: 7.396

10.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.